Calendrier des promotions Chugai Pharmaceutical Co., Ltd.
À propos de l'entreprise Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. вместе со своими дочерними компаниями занимается исследованиями, разработками, производством, продажей, импортом и экспортом фармацевтических препаратов в Японии и за рубежом. Препараты компании для онкологии в основном включают Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva и Xeloda; остеопороз, включая Actemra, Edirol и Bonviva; заболевания почек состоят из Мирцеры и Оксарола; и неврология/другие заболевания включают Hemlibra, CellCept и Enspryng. plus de détailsGrade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 9.84 | 1 |
| P/BV | 6.06 | 1 |
| P/E | 29.74 | 6 |
Efficacité
| Nom | Signification | Grade |
| ROA | 18.71 | 6 |
| ROE | 21.96 | 7 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 2.06 | 5.15 |
| DSI | 0.9286 | 9.29 |
| Croissance moyenne du dividende | 21.34 | 10 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 0.0237 | 10 |
| Debt/Ratio | 0.0061 | 10 |
| Debt/Equity | 0.1614 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 48.75 | 6 |
| Rentabilité Ebitda, % | 90.57 | 9 |
| Rentabilité EPS, % | 80.31 | 9 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 7 549 ¥ | 0 ¥ | 0 ¥ | -1.35 % | 0 % | 0 % |
| common.calendar.number_days.7d | 7 763 ¥ | 7 447 ¥ | 7 763 ¥ | -4.07 % | 0 % | 0 % |
| common.calendar.number_days.30d | 7 560 ¥ | 7 332 ¥ | 7 763 ¥ | -1.49 % | 0 % | 0 % |
| common.calendar.number_days.90d | 6 718 ¥ | 6 286 ¥ | 8 620 ¥ | 10.85 % | 0 % | 0 % |
| common.calendar.number_days.180d | 6 625 ¥ | 6 286 ¥ | 8 620 ¥ | 12.41 % | 0 % | 0 % |
| common.calendar.number_days.1y | 7 336 ¥ | 4 942 ¥ | 8 620 ¥ | 1.51 % | 0 % | 0 % |
| common.calendar.number_days.3y | 3 609 ¥ | 3 215 ¥ | 8 620 ¥ | 106.35 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0 ¥ | 3 215 ¥ | 8 620 ¥ | 0 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 ¥ | 3 215 ¥ | 8 620 ¥ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 7 251 ¥ | 6 286 ¥ | 8 620 ¥ | 2.7 % | 0 % | 0 % |
Principaux propriétaires
Contenu dans l'ETF
| ETF | Partager, % | Rentabilité pour l'année, % | Commission, % |
| Knowledge Leaders Developed World ETF | 1.17026 | -2.72 | 0.75 |
| Direxion Daily Japan Bull 3x Shares | 0.57578 | 6.34 | 0.45 |
| VictoryShares Developed Enhanced Volatility Wtd ETF | 0.1751 | 0.8332 | 0.51 |
| IQ 500 International ETF | 0.10409 | -4.21 | 0.25 |
| 0,51 | 0,06 | 0,49 |
|---|
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Osamu Okuda | President, CEO & Representative Director | 218M | 1963 (62 année) |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | N/A | |
| Mr. Shinji Hidaka | Executive VP and Head of Marketing & Sales Division | N/A | |
| Mr. Yoshiyuki Yano | Executive Vice President | N/A | |
| Mr. Junichi Ebihara | Executive Vice President | N/A | |
| Mr. Tetsuya Yamaguchi | Executive VP and Head of Project, Lifecycle Management & Foundation Medicine Unit | N/A | |
| Ms. Satoko Shisai | Executive VP & Head of Digital Transformation Unit | N/A | 1963 (62 année) |
| Dr. Tomoyuki Igawa Ph.D. | Associate VP & Head of Translational Research Division | N/A | |
| Dr. Kaori Ouchi | VP & Head of Drug Safety Division | N/A | |
| Mr. Nobuya Ishii | Head of Science & Technology Intelligence Dept., Project and Lifecycle Management Unit | N/A |
Informations sur l'entreprise
Adresse: Japan, Chuo -, 2-1-1 Nihonbashi-Muromachi - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.chugai-pharm.co.jp
Site web: https://www.chugai-pharm.co.jp
